株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

世界の睡眠薬市場

Sleeping Pills

発行 Global Industry Analysts, Inc. 商品コード 134317
出版日 ページ情報 英文 354 Pages
納期: 即日から翌営業日
価格
こちらの商品の販売は終了いたしました。
Back to Top
世界の睡眠薬市場 Sleeping Pills
出版日: 2010年08月01日 ページ情報: 英文 354 Pages

当商品の販売は、2016年07月01日を持ちまして終了しました。

概要

当レポートでは、世界の睡眠薬市場について調査し、市場のセグメンテーション、主な睡眠薬の概要、パイプライン分析、地域別動向、業界活動、参入する企業のプロファイルと競合状況などをまとめ、概略下記の構成でお届けいたします。

第1章 イントロダクション、方法論、製品定義

第2章 エグゼクティブサマリ

  • 業界概要
    • 安全性問題とジェネリック訳
    • 弱体化したパイプライン
    • 市場見通し
    • 睡眠障害
    • 米国が世界市場を牽引
    • 睡眠薬の効能に疑問を呈する研究
  • 睡眠薬市場セグメンテーション
  • 世界の主要な睡眠薬
  • 睡眠障害パイプライン分析
  • 製品概要
  • 地域別市場見通し
    • 米国
    • 欧州
    • 日本
    • 台湾
  • 近年の業界活動
  • 主要企業
  • 世界市場見通し

第3章 競合状況

  • 企業プロファイル:34社(事業部・子会社含め39社)
    • 米国
    • カナダ
    • 日本
    • 欧州
    • アジア太平洋地域(日本を除く)
目次
Product Code: MCP-6368

Abstract

This report analyzes the Global market for Sleeping Pills in US$ Million. Annual estimates and forecasts are provided for the period of 2007 through 2015. Also, a six-year historic analysis is provided for this market. The report profiles 34 companies including many key and niche players such as Actelion Pharmaceuticals Ltd., Abbott India Limited, Apotex Inc., Aurobindo Pharma Limited, Caraco Pharmaceutical Laboratories, Ltd., Dr. Reddy' s Laboratories Limited, H. Lundbeck A/S, King Pharmaceuticals Inc., Neurocrine Biosciences, Ranbaxy Laboratories Limited, Roxane Laboratories, Inc., Sepracor Inc ., Sanofi-aventis, Somaxon Pharmaceuticals Inc., Synthon BV, Takeda Pharmaceutical Company Limited, and Transcept Pharmaceuticals, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
  • Quantitative Techniques & Analytics
  • Product Definition and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • Safety Concerns and Generics Characterize the Market
  • "Perfect" Treatment Option Continues to Evade Insomnia Therapeutics Arena
  • A Market Characterized by Weak Pipeline
  • Market Outlook
  • Sleep Disorders - Not Confined to Elderly Alone
  • US Leads the Global Market for Sleeping Pills
  • Table 1: US Prevalence of Chronic Insomnia by Type: 2008 (includes corresponding Graph/Chart)
  • Studies Cast Doubt On the Efficacy of Sleeping Pills

2. SLEEPING PILLS MARKET SEGMENTATION

  • Market Categorization
  • Table 2: Select Benzodiazepines and Non-Benzodiazepines Worldwide
  • Benzodiazepines Loose Sheen Due to Associated Side Effects
  • ' Z' Drugs Outshine Benzodiazepines with Lesser Adverse Effects
  • Table 3: Sales of Select Leading Sleeping Pills Worldwide
  • Melatonin Receptor Agonist Hypnotic
  • Rozerem - The Only Drug without the Risk of Dependency

3. MAJOR SLEEPING PILLS WORLDWIDE

  • Zolpidem (Sanofi-Aventis/Various)
  • Ambien CR (Sanofi-Aventis)
  • Lunesta (Sepracor)
  • Intermezzo (Transcept)
  • Sonata (King Pharmaceuticals)
  • Imovane (Sanofi-Aventis)

4. SLEEP DISORDER PIPELINE ANALYSIS

5. PRODUCT OVERVIEW

  • Insomnia - A Review
  • Impact on Day-to-day Life
  • Insomnia: An Under-Diagnosed Disease
  • Middle-Of-The-Night Insomnia
  • What are Sleeping Pills?
  • When it Should be Taken?
  • Side Effects - A Key Concern
  • Natural Treatment of Insomnia
  • Eye Cells - A New Potential Target for Sleeping Pills

6. REGIONAL MARKET PERSPECTIVE

6a. THE UNITED STATES

  • Economic Woes Drive Usage of Sleeping Pills
  • Table 4: Sleeping Pills Prescription Volume in the US: 2006-2008 (includes corresponding Graph/Chart)
  • Table 5: Sleeping Pills Prescription Volume in the US by Drug: 2006-2008 (In Million) (includes corresponding Graph/Chart)
  • Dangerous Signs for Americans
  • OTC Sleeping Aids Market Review
  • Table 6: Leading OTC Sleeping Aid Tablets in the US (2008): Percentage Breakdown of Value Sales for Simply Sleep, Unisom SleepGels, Unisom SleepTabs, Sleep MD, Sominex, Midnite, Breathe Right, Sleepinal, Private Label Brands and Others (includes corresponding Graph/Chart)
  • Table 7: Leading OTC Sleeping Aid Tablets in the US (2008): Percentage Breakdown of Volume Sales for Simply Sleep, Unisom SleepGels, Sominex, Unisom SleepTabs, Sleep MD, Midnite, Sleepinal, Breathe Right, Private Labels and Others (includes corresponding Graph/Chart)
  • Table 8: Leading OTC Sleeping Aid Liquid Drugs in the US Drug Stores (2007): Percentage Breakdown of Value Sales for Breathe Right, Snorestop, Bach Rescue Sleep, Nutramist Sleep Now, Nutranetics Liquid Sleep and Others (includes corresponding Graph/Chart)
  • Table 9: Leading OTC Sleeping Pills in US Drug Stores (2007): Percentage Breakdown of Value Sales for Simply Sleep, Unisom Sleepgels, Sleep MD, Unisom, Sominex and Others (includes corresponding Graph/Chart)
  • Table 10: Leading OTC Sleeping Pills in US Drug Stores (2007): Percentage Breakdown of Volume Sales for Simply Sleep, Unisom Sleepgels, Sominex, Unisom, Sleep MD and Others (includes corresponding Graph/Chart)

6b. EUROPE

  • Europe: A Major Market for Sleeping Pills
  • Table 11: European Prevalence of Chronic Insomnia by Type: 2008 (includes corresponding Graph/Chart)
  • Table 12: Sleeping Disorders in Europe (2008): Prevalence Rate by Age Group for Select European Countries - France, Germany, Italy, UK (includes corresponding Graph/Chart)
  • Table 13: Sleeping Disorders in Europe (2008): Prevalence Rate by Gender for Select European Countries - France, Germany, Italy, UK (includes corresponding Graph/Chart)

6c. JAPAN

  • Illegal Sales of Sleeping Pills Rampant in Japan

6d. TAIWAN

  • Sleeping Pills Sales Continue to Soar

7. RECENT INDUSTRY ACTIVITY

  • Somaxon Pharma Receives US FDA Approval for Silenor
  • Transcept Pharmaceuticals Merges with Novacea
  • Sepracor Files Lawsuits Against ANDA Filers for Eszopiclone
  • Dainippon Sumitomo Takes Over Sepracor
  • FDA Puts Two Pediatric Studies of Lunesta on Hold
  • Transcept Pharmaceuticals Signs Deal with Purdue Pharmaceutical Products
  • Sepracor Receives Approval for Lunesta Oral Tablet
  • FDA Approves Mylan' s ANDA for Zaleplon Capsules
  • GlaxoSmithKline Signs Agreement with Actelion
  • Lundbeck Launches Circadin® in Germany for Insomnia
  • Lundbeck Launches Circadin in the UK
  • Transcept Completes Phase III Study of Intermezzo, Files NDA
  • Evotec Scouts for Partners to Develop EVT 201
  • Aurobindo Pharma Receives FDA Approval for Zaleplon
  • Australia' s TGA Orders Boxed Warnings for Stilnox
  • Sepracor Obtains Positive Opinion for Approval of Lunivia from CHMP
  • Caraco Obtains FDA Approval for Generic Zolpidem
  • FDA Approves ANDA of Dr. Reddy' s Laboratories for Zolpidem Tartrate
  • Ranbaxy Obtains FDA Clearance to Market Generic Ambien®
  • Neurocrine Obtains Second Approvable Letter from FDA for Indiplon Capsules
  • Roxane Launches Zolpidem Tartrate Tablets

8. FOCUS ON SELECT PLAYERS

  • Actelion Pharmaceuticals Ltd. (Switzerland)
  • Abbott India Limited (India)
  • Apotex Inc. (Canada)
  • Aurobindo Pharma Limited (India)
  • Caraco Pharmaceutical Laboratories, Ltd. (US)
  • Dr. Reddy' s Laboratories Limited (India)
  • H. Lundbeck A/S (Denmark)
    • King Pharmaceuticals, Inc. (US)
    • Neurocrine Biosciences (US)
    • Ranbaxy Laboratories Limited (India)
    • Roxane Laboratories, Inc. (US)
    • Sepracor, Inc. (USA)
    • Sanofi-aventis (France)
    • Somaxon Pharmaceuticals, Inc. (US)
    • Synthon BV (The Netherlands)
    • Takeda Pharmaceutical Company Limited (Japan)
    • Transcept Pharmaceuticals, Inc. (US)

9. GLOBAL MARKET PERSPECTIVE

  • Table 14: World Recent Past, Current and Future Analysis for Sleeping Pills by Geographic Region - US, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
  • Table 15: World Historic Review for Sleeping Pills by Geographic Region - US, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)
  • Table 16: World 13-Year Perspective for Sleeping Pills by Geographic Region - Percentage Breakdown of Dollar Sales for US, and Rest of World Markets for Years 2003, 2009 and 2015

III. COMPETITIVE LANDSCAPE

Back to Top